Contrasting Diadexus (OTCMKTS:DDXS) & Nexalin Technology (NASDAQ:NXL)

Diadexus (OTCMKTS:DDXS) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.

Insider & Institutional Ownership

0.7% of Nexalin Technology shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Diadexus and Nexalin Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Diadexus	N/A	N/A	N/A
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Valuation and Earnings

This table compares Diadexus and Nexalin Technology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diadexus	N/A	N/A	N/A	N/A	N/A
Nexalin Technology	$300,000.00	25.60	-$8.22 million	($0.47)	-0.74

Diadexus has higher earnings, but lower revenue than Nexalin Technology.

Analyst Recommendations

This is a summary of current ratings for Diadexus and Nexalin Technology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diadexus	0	0	0	0	0.00
Nexalin Technology	1	0	0	0	1.00

Given Diadexus’ higher probable upside, equities research analysts clearly believe Diadexus is more favorable than Nexalin Technology.

About Diadexus

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.